Back

Avicanna Inc

Ticker: AVCNF
Add to portfolio Portfolio analysis in 2min
Stock Small-cap
Market cap
$22.65M
Forward P/E
0.00
Profit margin
-9.97%
Revenue growth QoQ
-1.90%
Beta
0.33
$0.08 -0.13%
Price as of 2026-09-21 · OTCQX

Performance by timeframe

Rolling returns
1 Month -14.24%
6 Months -36.88%
1 Year -56.17%
5 Years -36.52% p.a.-89.67%
Since inception -39.56% p.a.-97.13%
Calendar year returns
YTD -51.30%
2025 -20.20%
2024 -24.25%
2023 +11.20%
2022 -63.48%
2021 -33.12%

Key stats

Market cap
22.65M
Beta
0.33
52-week range
0.12 - 0.33
50-day MA
0.19
200-day MA
0.20
Section 1

Business overview

Company profile data from fundamentals.

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Country Canada
Exchange OTCQX
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -27.01%
ROA -10.93%
Profit margin -9.97%
Operating margin 1.49%
Revenue/share TTM 0.24
Revenue TTM 25.34M
EBITDA -3.19M
Gross profit TTM 13.51M
Beta 0.33

Valuation

Trailing P/E 0.00
Forward P/E 0.00
P/B 9.79
P/S 0.89
EV/EBITDA -1.68
EV/Revenue 1.11
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 0.00
Quarterly earnings growth 0.00%
Revenue TTM 25.34M
Reported quarters 19
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Shares outstanding 113.81M
Shares float 82.07M
Institutional ownership 0.00%
Insider ownership 26.94%
Short ratio 0.00

Details

Instrument metadata and source update timestamps.

Symbol AVCNF
Name Avicanna Inc
Asset type STOCK
Exchange OTCQX
Currency USD
Country USA
Code + exchange AVCNF.OTCQX
Fundamentals updated 2025-07-22

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.